Xencor - XNCR STOCK NEWS

Xencor (NASDAQ:XNCR) announced the appointment of Todd Simpson to its board of directors. Simpson brings over 40 years of experience in CFO roles and public accounting, most notably serving as CFO at Seagen Inc. until its 2023 acquisition.

During his 18-year tenure at Seagen, Simpson was instrumental in the development and commercialization of four oncology medicines across multiple indications in the US. He led the company's international expansion, resulting in the commercialization of three medicines in the Americas and Europe. His responsibilities included oversight of global finance, strategic planning, tax, treasury, corporate real estate, facilities, investor relations, corporate communications, and IT.

Simpson currently serves on the board of Shape Therapeutics and previously held board positions at Neoleukin Therapeutics, Aquinox Pharmaceuticals, and Life Science Washington. He is a certified public accountant and holds a B.S. in accounting and computer science from Oregon State University.

Xencor (NASDAQ:XNCR) reported its Q4 and full year 2024 financial results, highlighting strategic pipeline rebalancing focused on XmAb® drug candidates. The company ended 2024 with $706.7 million in cash and equivalents, projecting sufficient funding into 2028.

Q4 2024 revenue was $52.8 million, with full-year revenue at $110.5 million. The company reported a Q4 net loss of $45.6 million ($0.62 per share) and a full-year net loss of $232.6 million ($3.58 per share).

Key clinical updates include progress on XmAb942 for inflammatory bowel disease, XmAb819 for renal cell carcinoma, and XmAb541 for solid tumors. The company earned a $30 million milestone payment from Amgen and $4 million from Novartis in Q4 2024.

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for cancer and serious diseases treatment, has announced its participation in two major investor conferences. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York City on December 3, 2024, at 2:00 p.m. ET, and at the 7th Annual Evercore HealthCONx Conference in Coral Gables, Florida on December 4, 2024, at 3:50 p.m. ET. Live webcasts will be available on Xencor's website under the Investors section, with replays accessible for at least 30 days after the presentations.

Xencor (NASDAQ:XNCR) reported Q3 2024 financial results with revenues of $10.7 million, down from $59.2 million in Q3 2023. The company posted a net loss of $45.1 million, or $(0.71) per share. Cash position stood at $754.3 million after raising $201.3 million through a public offering. R&D expenses decreased to $58.2 million from $64.9 million year-over-year. The company highlighted progress in its clinical pipeline, including XmAb942 entering Phase 1 trials and partner Amgen advancing xaluritamig to Phase 3 for prostate cancer. Xencor expects to end 2024 with $690-710 million in cash, funding operations into 2028.

Xencor (NASDAQ: XNCR) has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, a high-potency extended half-life anti-TL1A antibody for inflammatory bowel disease. The Phase 1/2 randomized, double-blind, placebo-controlled study will be conducted in three parts: Phase 1 Part A for single-ascending dose cohorts, Part B for repeat doses in healthy volunteers, and Phase 2 Part C for ulcerative colitis patients. Initial data is expected in the first half of 2025. The company believes XmAb942's properties may offer improved clinical benefits and more convenient dosing compared to other anti-TL1A antibodies in development.

Xencor (NASDAQ: XNCR) has announced preclinical data on XmAb942, a high-potency, extended half-life anti-TL1A antibody for inflammatory bowel diseases. The data will be presented at UEG Week in Vienna. XmAb942 aims to be a best-in-class next-generation anti-TL1A antibody, offering superior potency and less frequent dosing compared to first-generation antibodies.

Key points:

• First subject dosing in Phase 1 healthy volunteer study expected in Q4 2024
• Initial data from single-ascending dose portion anticipated in H1 2025
• Preclinical data shows comparable or superior in vitro potency to first-generation anti-TL1A antibodies
• 23-day half-life in non-human primates, potentially supporting 8-12 week dosing in humans

Xencor (NASDAQ: XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and other serious diseases, has announced an upcoming change to its Board of Directors. Dagmar Rosa-Bjorkeson, who has served as a director since 2019, will not seek reelection at the 2025 Annual Meeting of Stockholders. Rosa-Bjorkeson plans to pursue another business opportunity.

Xencor is actively recruiting additional Board members with complementary skillsets. The company's CEO, Bassil Dahiyat, Ph.D., expressed gratitude for Rosa-Bjorkeson's contributions to the Board and its audit and nominating and governance committees, particularly her strategic guidance in advancing programs and rebalancing the company's portfolio.

Xencor (XNCR) has successfully closed its public offering, raising approximately $201.3 million in gross proceeds. The offering included 8,093,712 shares of common stock at $18.00 per share and 3,088,888 pre-funded warrants at $17.99 each. The underwriters fully exercised their option to purchase additional shares. Xencor plans to use the net proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering was made through an automatic shelf registration statement, with Leerink Partners, Raymond James, and RBC Capital Markets acting as joint book-running managers.

Xencor (XNCR) has priced its public offering of common stock and pre-funded warrants, aiming to raise $175 million. The offering includes 6,635,112 shares at $18.00 per share and 3,088,888 pre-funded warrants at $17.99 each. Underwriters have a 30-day option to purchase up to 1,458,600 additional shares. The clinical-stage biopharmaceutical company plans to use the proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering is expected to close around September 12, 2024, subject to customary conditions.